JFG
CRSP icon

Jefferies Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Jefferies Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
+24,001
New +$1.27M 0.01% 852
2024
Q1 		– Sell
-1
Closed -$63 – 1678
2023
Q4 		$63 Buy
+1
New +$55 ﹤0.01% 1638
2023
Q1 		– Sell
-4,271
Closed -$174K – 1684
2022
Q4 		$174K Buy
+4,271
New +$227K ﹤0.01% 1318

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jefferies Financial Group's CRSP Position: Q2 2026 in Review

Jefferies Financial Group opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 24,001 shares worth $1.31M. The stake represents 0.01% of the portfolio and ranks #852 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in CRSP as recently as Q4 2023.

Jefferies Financial Group first reported a position in CRSP in Q4 2022 and has held it in 3 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Jefferies Financial Group held 24,001 shares of CRISPR Therapeutics worth $1.31M as of Q2 2026.
  • CRISPR Therapeutics was a new Jefferies Financial Group position in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #852 holding.
  • Jefferies Financial Group first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.